Do analysts rate NIVF or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, NIVF or BMGL?

NewGenIvf Group has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.66 $9.88M N/A N/A Basel Medical Group $8.90M 0.85 -$9.50M N/A N/A

Is NIVF or BMGL more profitable?

Company Net Margins Return on Equity Return on Assets NewGenIvf Group N/A N/A N/A Basel Medical Group N/A N/A N/A

Does the media prefer NIVF or BMGL?

In the previous week, NewGenIvf Group had 2 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for NewGenIvf Group and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.16 indicating that Basel Medical Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Basel Medical Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NIVF or MGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NIVF or MGRX?

NewGenIvf Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.66 $9.88M N/A N/A Mangoceuticals $460K 17.21 -$20.64M -$1.01 N/A

Does the media refer more to NIVF or MGRX?

In the previous week, NewGenIvf Group had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for NewGenIvf Group and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.34 beat NewGenIvf Group's score of -0.16 indicating that Mangoceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mangoceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NIVF or AIDX?

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 800.90%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than NewGenIvf Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, NIVF or AIDX?

NewGenIvf Group has higher revenue and earnings than 20/20 Biolabs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.66 $9.88M N/A N/A 20/20 Biolabs $2.04M 3.47 -$3.74M -$0.28 N/A

Is NIVF or AIDX more profitable?

Company Net Margins Return on Equity Return on Assets NewGenIvf Group N/A N/A N/A 20/20 Biolabs N/A N/A N/A

Do analysts recommend NIVF or GXAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, NIVF or GXAI?

NewGenIvf Group has higher earnings, but lower revenue than Gaxos.ai. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NewGenIvf Group $4.73M 0.66 $9.88M N/A N/A Gaxos.ai $6.01M 1.01 -$3.90M -$0.50 N/A

Does the media refer more to NIVF or GXAI?

In the previous week, Gaxos.ai had 2 more articles in the media than NewGenIvf Group. MarketBeat recorded 5 mentions for Gaxos.ai and 3 mentions for NewGenIvf Group. Gaxos.ai's average media sentiment score of 0.83 beat NewGenIvf Group's score of -0.16 indicating that Gaxos.ai is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewGenIvf Group 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gaxos.ai 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IVF or NIVF?

INVO Fertility currently has a consensus price target of $20.00, indicating a potential upside of 1,797.53%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities research analysts plainly believe INVO Fertility is more favorable than NewGenIvf Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 NewGenIvf Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, IVF or NIVF?

NewGenIvf Group has lower revenue, but higher earnings than INVO Fertility. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INVO Fertility $7.53M 0.35 -$25.13M -$33.83 N/A NewGenIvf Group $4.73M 0.66 $9.88M N/A N/A

Does the media favor IVF or NIVF?

In the previous week, INVO Fertility and INVO Fertility both had 3 articles in the media. INVO Fertility's average media sentiment score of 0.70 beat NewGenIvf Group's score of -0.16 indicating that INVO Fertility is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INVO Fertility 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewGenIvf Group 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NewGenIvf Group (NIVF) Competitors

$0.53 -0.06 (-9.54%)

As of 09:47 AM Eastern

Compare

NIVF vs. BMGL, MGRX, AIDX, GXAI, and IVF

Should you buy NewGenIvf Group stock or one of its competitors? NewGenIvf Group's main competitors and comparable companies include Basel Medical Group (BMGL), Mangoceuticals (MGRX), 20/20 Biolabs (AIDX), Gaxos.ai (GXAI), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does NewGenIvf Group compare to Basel Medical Group?

NewGenIvf Group (NASDAQ:NIVF) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, NewGenIvf Group had 2 more articles in the media than Basel Medical Group. MarketBeat recorded 3 mentions for NewGenIvf Group and 1 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.16 indicating that Basel Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Basel Medical Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.2% of NewGenIvf Group shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NewGenIvf Group has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Basel Medical Group	N/A	N/A	N/A

NewGenIvf Group has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.66	$9.88M	N/A	N/A
Basel Medical Group	$8.90M	0.85	-$9.50M	N/A	N/A

Summary

NewGenIvf Group and Basel Medical Group tied by winning 4 of the 8 factors compared between the two stocks.

How does NewGenIvf Group compare to Mangoceuticals?

NewGenIvf Group (NASDAQ:NIVF) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

NewGenIvf Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NewGenIvf Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. NewGenIvf Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Mangoceuticals	-4,794.60%	-96.39%	-89.60%

66.2% of NewGenIvf Group shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 31.8% of NewGenIvf Group shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, NewGenIvf Group had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for NewGenIvf Group and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.34 beat NewGenIvf Group's score of -0.16 indicating that Mangoceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mangoceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NewGenIvf Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.66	$9.88M	N/A	N/A
Mangoceuticals	$460K	17.21	-$20.64M	-$1.01	N/A

Summary

NewGenIvf Group beats Mangoceuticals on 8 of the 11 factors compared between the two stocks.

How does NewGenIvf Group compare to 20/20 Biolabs?

NewGenIvf Group (NASDAQ:NIVF) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

In the previous week, NewGenIvf Group had 3 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for NewGenIvf Group and 0 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.16 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Overall Sentiment
NewGenIvf Group	Neutral
20/20 Biolabs	Neutral

66.2% of NewGenIvf Group shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NewGenIvf Group has higher revenue and earnings than 20/20 Biolabs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.66	$9.88M	N/A	N/A
20/20 Biolabs	$2.04M	3.47	-$3.74M	-$0.28	N/A

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 800.90%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than NewGenIvf Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
20/20 Biolabs	N/A	N/A	N/A

Summary

NewGenIvf Group and 20/20 Biolabs tied by winning 5 of the 10 factors compared between the two stocks.

How does NewGenIvf Group compare to Gaxos.ai?

NewGenIvf Group (NASDAQ:NIVF) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

NewGenIvf Group has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, Gaxos.ai had 2 more articles in the media than NewGenIvf Group. MarketBeat recorded 5 mentions for Gaxos.ai and 3 mentions for NewGenIvf Group. Gaxos.ai's average media sentiment score of 0.83 beat NewGenIvf Group's score of -0.16 indicating that Gaxos.ai is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewGenIvf Group	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gaxos.ai	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.2% of NewGenIvf Group shares are owned by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are owned by institutional investors. 31.8% of NewGenIvf Group shares are owned by company insiders. Comparatively, 3.2% of Gaxos.ai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NewGenIvf Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. NewGenIvf Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewGenIvf Group	N/A	N/A	N/A
Gaxos.ai	-64.81%	-38.79%	-36.99%

NewGenIvf Group has higher earnings, but lower revenue than Gaxos.ai.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewGenIvf Group	$4.73M	0.66	$9.88M	N/A	N/A
Gaxos.ai	$6.01M	1.01	-$3.90M	-$0.50	N/A

Summary

NewGenIvf Group beats Gaxos.ai on 6 of the 11 factors compared between the two stocks.

How does NewGenIvf Group compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

INVO Fertility currently has a consensus price target of $20.00, indicating a potential upside of 1,797.53%. Given INVO Fertility's stronger consensus rating and higher possible upside, equities research analysts plainly believe INVO Fertility is more favorable than NewGenIvf Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
NewGenIvf Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

INVO Fertility has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, NewGenIvf Group has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

In the previous week, INVO Fertility and INVO Fertility both had 3 articles in the media. INVO Fertility's average media sentiment score of 0.70 beat NewGenIvf Group's score of -0.16 indicating that INVO Fertility is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INVO Fertility	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewGenIvf Group	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewGenIvf Group has a net margin of 0.00% compared to INVO Fertility's net margin of -116.29%. NewGenIvf Group's return on equity of 0.00% beat INVO Fertility's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-116.29%	-85.54%	-31.05%
NewGenIvf Group	N/A	N/A	N/A

12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are held by institutional investors. 0.4% of INVO Fertility shares are held by insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NewGenIvf Group has lower revenue, but higher earnings than INVO Fertility.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$7.53M	0.35	-$25.13M	-$33.83	N/A
NewGenIvf Group	$4.73M	0.66	$9.88M	N/A	N/A

Summary

NewGenIvf Group beats INVO Fertility on 7 of the 13 factors compared between the two stocks.

Get NewGenIvf Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NIVF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NIVF vs. The Competition

Export

Metric	NewGenIvf Group	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.13M	$9.84B	$7.32B	$12.82B
Dividend Yield	N/A	2.55%	2.54%	10.79%
P/E Ratio	N/A	34.39	272.89	24.33
Price / Sales	0.66	4.89	596.33	74.53
Price / Cash	N/A	24.64	29.03	36.90
Price / Book	0.00	5.40	11.32	6.42
Net Income	$9.88M	$309.96M	$3.47B	$348.89M
7 Day Performance	-13.54%	1.01%	2.18%	0.51%
1 Month Performance	-52.18%	2.31%	7.61%	4.84%
1 Year Performance	-99.83%	15.71%	25.18%	17.04%

NewGenIvf Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NIVF NewGenIvf Group	2.0397 of 5 stars	$0.53 -9.5%	N/A	-99.8%	$3.13M	$4.73M	N/A	N/A
BMGL Basel Medical Group	0.4271 of 5 stars	$4.89 -6.0%	N/A	-77.7%	$7.65M	$14.55M	N/A	36	Analyst Upgrade Gap Down
MGRX Mangoceuticals	0.9567 of 5 stars	$0.42 -10.2%	N/A	-75.6%	$7.23M	$315.23K	N/A	3	Gap Down
AIDX 20/20 Biolabs	1.8457 of 5 stars	$0.51 -1.0%	$5.00 +878.5%	N/A	$6.26M	$2.05M	N/A	14
GXAI Gaxos.ai	1.2145 of 5 stars	$0.84 +3.3%	N/A	-57.8%	$6.00M	$1.93M	N/A	3	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NIVF) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewGenIvf Group (NIVF) Competitors

NIVF vs. BMGL, MGRX, AIDX, GXAI, and IVF

How does NewGenIvf Group compare to Basel Medical Group?

Summary

How does NewGenIvf Group compare to Mangoceuticals?

Summary

How does NewGenIvf Group compare to 20/20 Biolabs?

Summary

How does NewGenIvf Group compare to Gaxos.ai?

Summary

How does NewGenIvf Group compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIVF vs. The Competition

NewGenIvf Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewGenIvf Group (NIVF) Competitors

NIVF vs. BMGL, MGRX, AIDX, GXAI, and IVF

How does NewGenIvf Group compare to Basel Medical Group?

Does the media prefer NIVF or BMGL?

Do analysts rate NIVF or BMGL?

Do insiders & institutionals hold more shares of NIVF or BMGL?

Which has more volatility & risk, NIVF or BMGL?

Is NIVF or BMGL more profitable?

Which has preferable valuation & earnings, NIVF or BMGL?

Summary

How does NewGenIvf Group compare to Mangoceuticals?

Which has more volatility & risk, NIVF or MGRX?

Do analysts rate NIVF or MGRX?

Is NIVF or MGRX more profitable?

Do insiders & institutionals hold more shares of NIVF or MGRX?

Does the media refer more to NIVF or MGRX?

Which has better earnings and valuation, NIVF or MGRX?

Summary

How does NewGenIvf Group compare to 20/20 Biolabs?

Does the media favor NIVF or AIDX?

Do insiders & institutionals believe in NIVF or AIDX?

Which has preferable earnings & valuation, NIVF or AIDX?

Do analysts recommend NIVF or AIDX?

Is NIVF or AIDX more profitable?

Summary

How does NewGenIvf Group compare to Gaxos.ai?

Which has more risk and volatility, NIVF or GXAI?

Does the media refer more to NIVF or GXAI?

Do analysts recommend NIVF or GXAI?

Do insiders and institutionals hold more shares of NIVF or GXAI?

Is NIVF or GXAI more profitable?

Which has higher earnings & valuation, NIVF or GXAI?

Summary

How does NewGenIvf Group compare to INVO Fertility?

Do analysts prefer IVF or NIVF?

Which has more volatility & risk, IVF or NIVF?

Does the media favor IVF or NIVF?

Is IVF or NIVF more profitable?

Do insiders and institutionals hold more shares of IVF or NIVF?

Which has preferable valuation & earnings, IVF or NIVF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NIVF vs. The Competition

NewGenIvf Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools